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Prognosis in Cutaneous Graft-versus-Host Disease
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Graft-versus-host disease (GVHD) remains a common and potentially life-threatening complication of allogeneic
hematopoietic stem cell transplantation. In the skin, GVHD can present in an acute (aGVHD), chronic lichenoid
(clGVHD), or chronic sclerotic form (csGVHD). Measuring peripheral blood levels of the keratinocyte-derived
protease inhibitor elafin has recently emerged as a promising tool for the diagnosis of cutaneous aGVHD. We
evaluated whether the analysis of elafin expression in skin would allow distinguishing aGVHD from drug
hypersensitivity rashes (DHR) and whether cutaneous elafin expression would correlate with disease severity or
altered prognosis of aGVHD and clGVHD/csGVHD. Skin biopsies from aGVHD (n¼ 22), clGVHD (n¼ 15),
csGVHD (n¼ 7), and DHR (n¼ 10) patients were collected and epidermal elafin expression and its association
with diverse clinical/histological parameters were analyzed. Acute GVHD and DHR displayed varying degrees of
elafin expression. No elafin was detectable in csGVHD, whereas the molecule was increased in clGVHD
as compared with aGVHD. Elafin-high aGVHD/clGVHD lesions presented with epidermal thickening and
were associated with poor prognosis—i.e., decreased overall survival in aGVHD and corticosteroid resistance
in clGVHD. Although cutaneous elafin does not seem to discriminate aGVHD from DHR lesions, our study
strongly suggests an association between cutaneous elafin expression and poor prognosis for patients with
cutaneous GVHD.
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INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (HCT) is a
potentially curative therapy for numerous hematological dis-
orders. The broader application of HCT is limited by its most
frequent and potentially life-threatening complication, namely
graft-versus-host disease (GVHD; Ferrara et al., 2009). GVHD
can occur in an acute or a chronic form (aGVHD and
cGVHD), in both of which the skin is the most frequent and
usually the first affected organ (Higman and Vogelsang, 2004;
Ferrara et al., 2009). Despite major progresses in HCT practice,
available treatment options for GVHD patients are limited and
corticosteroids remain the first-line therapy for both aGVHD
and cGVHD (Wolff et al., 2010, 2013). Early diagnosis of skin
involvement in GVHD is crucial for an appropriate therapy in
an attempt to prevent disease progression.
Skin aGVHD usually presents as a maculopapular or
morbilliform rash (Wagner and Murphy, 2005; Hausermann
et al., 2008). Histopathological features of aGVHD include
satellite cell necrosis (dyskeratotic keratinocytes surrounded
by lymphocytes) and the vacuolization of basal epidermal
layers. Chronic cutaneous GVHD shares major characteristics
with lichen planus during the early stages of disease
progression (chronic lichenoid GVHD, clGVHD). Clinically,
this is evidenced by the presence of lichenoid papules. Histo-
pathologically, clGVHD shows a wedge-shaped hypergra-
nulosis and basal cell liquefaction of the epidermis, as well
as a prominent band-like lymphocytic infiltrate in the dermis.
In a more advanced stage, cGVHD tends to exhibit signs of
sclerosis (chronic sclerotic GVHD, csGVHD).
It is challenging both clinically and histopathologically to
differentiate between aGVHD and its main differential diag-
nosis, namely drug hypersensitivity rashes (DHR). This dis-
tinction has critical therapeutic consequences—i.e., either the
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initiation of a systemic corticosteroid regimen to control
GVHD or the discontinuation of the drug(s) causing DHR.
Numerous approaches have aimed at identifying parameters
to diagnose aGVHD more accurately and to distinguish it
from DHR (Byun et al., 2011). Elafin has (in a retrospective
proteomic approach) been identified as an accurate plasmatic
biomarker of cutaneous aGVHD that correlates with disease
severity and even has a prognostic value (Paczesny et al.,
2010; Levine et al., 2012). The investigators also showed that
elafin was overexpressed in seven out of ten aGVHD skin
specimens but was absent in a similar number of DHR
biopsies (Paczesny et al., 2010).
Elafin is a serine protease inhibitor that is mostly pro-
duced by epithelial cells. In the skin, keratinocytes are the
main source of this molecule. Although elafin is not
detectable in normal skin, it is secreted abundantly in psoriasis
and other inflammatory (Tanaka et al., 2000; Kamsteeg
et al., 2010), as well as neoplastic (Alkemade et al., 1993),
skin disorders. Elafin acts in various ways on the cutaneous
immune homeostasis by not only exerting antiprotease
effects but also immunomodulatory and antiproliferative
ones (Williams et al., 2006; Verrier et al., 2012). Hence,
keratinocyte-derived elafin seems to favor the development
of a T helper type1 response (Roghanian et al., 2006),
but it can also enhance the resolution of inflammation by
facilitating phagocytosis of apoptotic leukocytes (Williams
et al., 2006).
In this study, we sought to analyze cutaneous elafin
expression in the acute and chronic forms of GVHD and to
explore whether cutaneous elafin was associated with distinct
histopathological or clinical features related to the severity or
outcome of GVHD. In addition, we wanted to evaluate the
potential of cutaneous elafin as a marker to distinguish
aGVHD from DHR.
RESULTS
Varying degrees of elafin expression in aGVHD and DHR
To explore the potential of cutaneous elafin as a marker to
distinguish aGVHD from DHR, we quantified cutaneous elafin
in these two diseases at both the mRNA and protein levels.
We performed a quantitative real-time polymerase chain
reaction (reverse transcriptase-PCR) with RNA extracted from
whole-skin biopsies of 22 aGVHD patients, as well as 10 DHR
patients. This analysis of elafin mRNA levels (normalized to
healthy control skin) did not reveal any difference between
aGVHD (n¼22) and DHR (n¼10; Figure 1a), and we could
confirm our data in an independent cohort of aGVHD patients
(Supplementary Figure S1 online).
In accordance with this finding, immunohistochemistry (IH)
staining for elafin on paraffin sections of the same patients
revealed various elafin expression patterns (Figure 1b and e).
In some sections, elafin was restricted to the stratum granu-
losum, whereas in others it extended to the stratum spinosum
(Figure 1e). In contrast, healthy control skin samples (n¼7)
were completely negative, and lesional psoriasis skin (stained
as a positive control, n¼ 5) was highly positive for elafin
(Figure 1c). The percentage of elafin-positive keratinocytes
as quantified using the HistoFAXS software (TissueGnostics
GmbH, Vienna, Austria) was not significantly higher in
aGVHD as compared with DHR (Figure 1d).
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Figure 1. Various elafin expression patterns in cutaneous graft-versus-host disease (GVHD). (a) mRNA expression of elafin in acute graft-versus-host disease
(aGVHD) and drug hypersensitivity reaction (DHR), normalized to healthy control (HC) skin. Quantitative real-time reverse transcriptase-PCR (RT-PCR) was
performed after TRizol lysis of skin biopsies. (b, c) Representative pictures (scale bar¼100mm in all pictures) of immunohistochemistry (IH) elafin staining in DHR,
HC, and psoriasis. Images were taken using a PixeLINK PL-B623CF color digital camera (Zeiss, Oberkochen, Germany). (d) The percentage of elafin-positive
keratinocytes in aGVHD as compared with DHR measured using HistoQuest imaging analysis software. Expression in HC and lesional psoriatic skin is shown as a
negative control and a positive control, respectively. (e, f) Pictures of elafin staining in aGVHD and chronic lichenoid graft-versus-host disease (clGVHD) skin (two
different patients each) with corresponding hematoxylin and eosin (HE) sections shown below (scale bar¼100mm in all pictures). Blue arrows indicate correlation
of epidermal thickness with increased elafin expression. The orange arrow points to the prominent inflammatory infiltrate in an elafin-high skin area. (g) Percentage
of elafin-positive keratinocytes in aGVHD vs. clGVHD. Cutoff (at 20%) between the elafin-high and the elafin-low groups.
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Different patterns of epidermal elafin expression in aGVHD and
clGVHD
As elafin expression has only been analyzed in cutaneous
aGVHD, we asked whether the chronic forms of GVHD
would exhibit similar elafin expression patterns. To explore
keratinocytic elafin expression in these patient groups, we
performed an IH staining for elafin on skin sections of 15
clGVHD and seven csGVHD patients. Although no, or only
very low, elafin expression was seen in csGVHD (data not
shown), clGVHD lesions exhibited various expression pat-
terns. Only in a few sections elafin staining was restricted to
the stratum granulosum, whereas in the other skin specimens
it was detectable in the stratum spinosum with an either
patchy or continuous pattern (Figure 1f). The percentage
of elafin-positive keratinocytes was significantly higher
(P¼ 0.013) in clGVHD as compared with aGVHD (Figure 1g).
Elafin expression is associated with epidermal thickening
The expression of elafin in aGVHD and clGVHD skin biopsies
was heterogeneous. To evaluate a possible association of
upregulated elafin expression with histopathological or clin-
ical features, aGVHD and clGVHD patient cohorts were
divided into an elafin-low subgroup and an elafin-high
subgroup (cutoff shown in Figure 1g). Patients were consid-
ered elafin-low if the elafin staining was restricted to the
stratum granulosum, which corresponded to less than 20%
elafin-positive keratinocytes. According to this classification,
27% of the aGVHD (6/22) and 60% of the clGVHD patients
(9/15) belonged to the elafin-high groups.
To address the potential association of elafin expression
with distinct histopathological features, parameters known to
be relevant (Lerner et al., 1974) for GVHD diagnosis were
assessed on hematoxylin and eosin (HE)–stained skin sections.
The parameters analyzed were vacuolization, dyskeratosis,
overall inflammatory infiltrate, hyperkeratosis, and
hypergranulosis, as well as epidermal thickness. These
features were evaluated by a blinded histopathologist (PP)
and compared between elafin-high versus elafin-low patients
of our aGVHD and clGVHD cohorts.
Dyskeratosis and vacuolization were not associated with
higher elafin expression in aGVHD or clGVHD
(Supplementary Figure S2a–b online). Epidermal thickening,
assessed as the mean number of epidermal cell layers found in
a section, correlated with increased elafin expression
(Figure 1e and f, blue arrows on HE images; Figure 2a). A
statistically significant difference was found between elafin-
high and elafin-low groups in aGVHD (P¼0.003) and
clGVHD (P¼0.008). Additional signs of epidermal thickening
that could be observed in clGVHD, i.e., acanthosis and
hypergranulosis, were more often present in elafin-high speci-
mens (Supplementary Figure S2c–d online).
We found the inflammatory infiltrate to be more prominent
in elafin-high skin areas (Figure 1f, HE image, Figure 2b and
c). To substantiate this finding, we performed immunofluor-
escence stainings of CD4þ and CD8þ T cells, as well as
regulatory T cells. This revealed a trend toward higher elafin
expression in the presence of a prominent CD4þ and CD8þ
T-cell infiltrate (Supplementary Figure S3a–c online)
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Figure 2. Epidermal thickening and a prominent CD4þ T-cell infiltrate in elafin-high graft-versus-host disease (GVHD) lesions. (a) Mean number of epidermal
cell layers and the percentage of elafin-positive keratinocytes in acute graft-versus-host disease (aGVHD)/chronic lichenoid graft-versus-host disease (clGVHD)
patients. The mean number of cell layers was calculated as (minimal number of cell layers epidermisþmaximal number of layers epidermis)/2. (b, c)
Quantification of the overall inflammatory infiltrate in elafin-low versus elafin-high groups of the aGVHD and clGVHD cohorts. (d) Quantitative analysis of the
dermal T-cell infiltrate (T cells: CD3þ , CD4þ T cells: CD3þCD4þ , CD8þ T cells: CD3þCD8þ ; regulatory T cells (Treg) cells: CD4þFoxp3þ ) in elafin-high as
compared with elafin-low aGVHD skin lesions. (e) Representative images of immunofluorescence (IF) stainings of CD4þ T cells merged with DAPI in an elafin-
high and an elafin-low aGVHD skin lesion. Scale bar¼ 50mm in both pictures. The epidermis is located on the upper side in both images. Images were taken using
a PCO PixelFly camera (Zeiss).
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with an increase of CD4þ T cells in the dermis of elafin-high
aGVHD samples as compared with elafin-low ones (Figure 2d
and e). Regulatory T cells were almost absent in all of the
skin lesions.
TNFa and TGFb are dysregulated in elafin-high GVHD skin
lesions
On the basis of the observation that increased elafin
expression was associated with altered histopathological
features, i.e., epidermal thickening and a more prominent
inflammatory infiltrate, we were interested in the mechanisms
driving elafin expression in GVHD.
We hypothesized that the expression of cytokines
known to modulate keratinocytic elafin release could be
altered in skin displaying high elafin expression. Therefore,
we quantified mRNA levels of IL-1b and tumor necrosis
factor alpha (TNFa), both potent inducers, and transforming
growth factor beta (TGFb), an inhibitor of elafin secretion
by keratinocytes. We found a significant (P¼0.03) increase
of TNFa (Figure 3a) in elafin-high as compared with
elafin-low aGVHD skin. In contrast, TGFb was downregulated
(P¼ 0.03) in elafin-high lesions as compared with elafin-
low clGVHD lesions (Figure 3b). Hence, cytokines appear
to have a role in the distinct expression patterns of elafin in
GVHD.
Elafin is associated with poor prognosis of GVHD
Finally, we sought to determine whether high elafin expres-
sion in cutaneous GVHD had a clinical correlate and was
associated with a more severe form or poor prognosis of the
disease. Clinical characteristics related to the severity or the
outcome of GVHD were analyzed and compared between
elafin-high and elafin-low groups of aGVHD and clGVHD
patients. The analysis of these parameters revealed that
neither the histological or clinical staging (Supplementary
Table S1 online) of GVHD skin involvement nor the GVHD
overall grading differed between elafin-high and elafin-low
groups of the aGVHD or clGVHD cohorts. However, the
prognosis of patients was worse in aGVHD and clGVHD
patients with elafin-high skin lesions. Elafin-high aGVHD
patients had a significantly decreased 2-year overall survival
(P¼ 0.003; Figure 3c) and elafin-high clGVHD patients were
more frequently refractory to corticosteroids (P¼ 0.006;
Figure 3d).
DISCUSSION
In the present study, we could show that both aGVHD and
clGVHD skin lesions exhibit diverse elafin expression patterns
associated with distinct molecular, histopathological, and
clinical features. In addition, the analysis of cutaneous elafin
did not allow distinguishing between aGVHD and DHR skin
eruptions. We report comparable levels of elafin expression at
the mRNA and protein levels in both DHR and aGVHD
rashes. Remarkably, elafin expression was higher in clGVHD
as compared with aGVHD but not detectable in csGVHD. In
both aGVHD and clGVHD, high elafin expression was
associated with epidermal thickening and a trend toward a
more prominent T-cell infiltrate. Although none of the clinical/
histological grading criteria were associated with high elafin
expression, elafin-high aGVHD patients had a decreased
overall survival and clGVHD patients were more frequently
refractory to corticosteroids. TNFa, a potent inducer of elafin
expression in keratinocytes, was increased in elafin-high
as compared with elafin-low aGVHD skin, whereas the
inhibitor TGFb was downregulated in elafin-high clGVHD
skin specimens.
The distinction between acute cutaneous GVHD and DHR
is challenging, yet therapeutically important. Our findings
from two independent cohorts strongly indicate that the
analysis of elafin in the skin is not a useful marker to support
the histopathological diagnosis of cutaneous aGVHD and to
discriminate between this disease and DHR. Our observations
partially differ from those made by others (Paczesny et al.,
2010) who stained for elafin in the skin of aGVHD (n¼ 10), as
well as of DHR (n¼10) patients, and found expression in the
majority of aGVHD (70%) but in none of the DHR samples.
Conceivably, these divergent results are because of differences
in either clinical, procedural, or data collection/analysis-
related factors. Potentially critical clinical parameters in
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Figure 3. High elafin expression in graft-versus-host disease (GVHD) is
associated with corticosteroid unresponsiveness and decreased overall
survival (OS). (a,b) Comparison of mRNA expression of tumor necrosis factor
alpha (TNFa), IL-1b, and transforming growth factor beta (TGFb) in elafin-high
as compared with elafin-low groups of (a) acute graft-versus-host disease
(aGVHD) and (b) chronic lichenoid graft-versus-host disease (clGVHD)
patients. Quantitative real-time reverse transcriptase-PCR (RT-PCR) was
performed after TRizol lysis of skin biopsies. Data are normalized to b2m of
each specimen and represent the mean±SD of (log2) fold change in mRNA
expression relative to healthy control (HC) skin (n¼ 10). (c) Cumulative
survival after 2 years of elafin-high versus elafin-low aGVHD patients shown as
a Kaplan–Meier curve. (d) Percentage of corticosteroid-resistant clGVHD
patients in the elafin-high versus elafin-low groups.
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Table 1. Patient characteristics
aGVHD (n¼ 22) clGVHD (n¼15) DHR (n¼10)
Patient age1 47.6±13.2 46.8±13.2 53.7±13.9
Patient gender
F 11 9 4
M 11 6 6
Skin clinical staging
Stage 1 4 3 Generalized MPR2 7
Stage 2 7 7 Erythrodermia2 1
Stage 3 11 5 Erythrodermia, few blisters3 1
Suberythrodermia, mucosal enanthema4 1
Diagnosis before HCT
ALL 2 6
AML 9 5
sAML 3 2
CLL 1
CML 1
HL 1
NHL 4 1
MDS 2
Stem cell source
PBSC 20 15
BM 2
Donor type
MUD 13 6
MMUD 6 5
SIB 3 4
Gender mismatch (donor/recipient)
F/F 10 2
M/F 1 7
F/M 2
M/M 11 4
Conditioning
RIC 13 8
MAC 9 7
GVHD prophylaxis
CSA MMF 12 5
CSA MTX 9 9
CSA 1 1
Abbreviations: aGVHD, acute graft-versus-host disease; ALL, acute lymphoid leukemia; AML, acute myeloid leukemia; BM, bone marrow; clGVHD, chronic
lichenoid graft-versus-host disease; CLL, chronic lymphoid leukemia; CML, chronic myeloid leukemia; CSA, cyclosporine A; DHR, drug hypersensitivity
rashes; F, female; HCT, allogeneic hematopoietic stem cell transplantation; HL, Hodgkin’s lymphoma; M, male; MAC, myeloablative conditioning; MDS,
myelodysplastic syndrome; MMF, mycophenolate mofetil; MMUD, mismatched unrelated donor; MPR, maculopapular rash; MTX, methotrexate; NHL, non-
Hodgkin’s lymphoma; PBSC, peripheral blood stem cells; RIC, reduced-intensity conditioning; sAML, secondary acute myeloid leukemia; SIB, sibling; TEN,
toxic epidermal necrolysis.
1Mean (years) ±SD.
2No blisters, no mucosal involvement.
3No mucosal involvement (no TEN).
4No blisters (no TEN).
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DHR patients are the diversity of clinical manifestations
(in our patients: 7/10 generalized maculopapular rash, 3/10
(sub)erythroderma; details see Table 1) and the HCT status
of patients (HCT recipients vs. non-HCT recipients). DHR
manifestations in the study of Paczesny et al. (2010) were
denominated as maculopapular rash but not further detailed.
A limitation of our work is that DHR patients of the study by
Paczesny et al. (2010), but not of our study, were HCT
recipients. Unpublished data from our lab indicate, however,
that elafin expression is not altered in HCT patients (n¼ 4) as
compared with non-HCT patients with DHR. In aGVHD
patients, the underlying diagnosis before HCT, as well as the
course and severity of the disease (see Table 1), could be
important. Our data suggest that disease prognosis rather than
severity is associated with an altered elafin expression. Mean-
while, it is difficult to evaluate the potential impact of the
other parameters because Paczesny et al. (2010) provided
information of their entire aGVHD plasma elafin validation
cohort (n¼58), but not specifically of the ten aGVHD patients
(part of this cohort), in which elafin expression was evaluated
in the skin. Among procedural aspects, biopsy timing, as well
as the type of conditioning and GVHD prophylaxis, could be
important but are not specified for the Paczesny et al. (2010)
cohort. With regard to data analysis/collection, IH elafin
staining in the Paczesny study was evaluated by two blinded
independent pathologists considering sections to be positive if
more than 50% of the epidermis was stained. We used the
HistoFAXS software system to more precisely and objectively
measure the percentage of elafin-positive keratinocytes and
concurrently quantified elafin expression at an mRNA level.
These methodological differences cannot sufficiently explain
the divergent results, as a re-analysis of our data using the
method of Paczesny et al. (2010) (data not shown) confirmed
our findings.
The various mechanisms through which elafin acts on the
cutaneous immune homeostasis make it a candidate effector
molecule of interest in the pathogenesis of GVHD. Besides its
major role as an inhibitor of neutrophil-derived elastases,
elafin has antimicrobial, immunomodulatory, and tissue-
remodeling properties (Williams et al., 2006; Verrier et al.,
2012).
Particularly interesting with regard to our results is the
observation that elafin can inhibit elastase-induced keratino-
cyte proliferation (Meyer-Hoffert et al., 2004). In contrast to
normal skin where it is not detectable (Pfundt et al., 1996;
Kamsteeg et al., 2010), elafin is abundantly secreted in diverse
skin conditions exhibiting hyperproliferative features.
These include psoriasis (Kamsteeg et al., 2010), wound
healing (van Bergen et al., 1996), diverse skin neoplasms
(Alkemade et al., 1993), and lichen planus (unpublished data
from our lab). Our study not only revealed increased elafin
expression in clGVHD, another disease characterized by
keratinocytic hyperproliferation (Shulman et al., 2006), but
also demonstrated a strong association between high elafin
expression and epidermal thickening. On the basis of these
observations, it would be conceivable that elafin production
may represent a compensatory mechanism to regulate
keratinocytic hyperproliferation.
This hypothesis is further supported by our observation that
TNFa mRNA expression is slightly increased in elafin-high
aGVHD specimens. TNFa potently induces elafin production
in keratinocytes and is a key mediator in aGVHD, where it is
abundantly secreted after conditioning therapy for HCT. The
TNFa upregulation and TGFb (an inhibitor of elafin release)
downregulation are in line with the previously described
concept that elafin production by keratinocytes is triggered
during inflammatory reactions characterized by high levels of
TNFa and IL-1b. Nevertheless, this finding needs to be
confirmed in a larger cohort.
In addition, elafin has been shown to favor the development
of T helper type1 responses by enhancing dendritic cell
accumulation and activation. As we could recently demon-
strate that cutaneous clGVHD is characterized by a mixed T
helper type1/ T helper type17 response (Bru¨ggen et al., 2014),
higher elafin expression in clGVHD supports this idea. It
remains to be elucidated whether our finding of an increased
CD4þ T-cell infiltrate in elafin-high aGVHD is, at least
partially, attributable to elafin production. Alternatively, it
might be due to molecules that are concurrently increased
with elafin (such as TNFa).
Although in our hands cutaneous elafin expression is not a
useful diagnostic marker for aGVHD and does not correlate
with disease severity, our results show that high elafin
expression in GVHD skin lesions heralds a worsened disease
prognosis—i.e., decreased overall survival in aGVHD patients
and corticosteroid unresponsiveness in clGVHD patients.
Epidermal elafin could therefore serve as a predictive marker,
provided that the diagnosis of GVHD has unequivocally been
established. Studies by others (Paczesny et al., 2010) indicate
that plasmatic elafin levels could be helpful diagnostic and
predictive biomarkers in cutaneous aGVHD. Preliminary data
from our lab support this notion (data not shown).
In conclusion, our study shows that elafin expression in the
skin is associated with poor prognosis in both the acute and
chronic forms of cutaneous GVHD. Staining for cutaneous
elafin in addition to the standard HE histopathological evalua-
tion can be easily done, and it may facilitate the early
identification of patients with an unfavorable prognosis,
provided that the diagnosis of GVHD has previously
been established. This would allow the introduction of
alternative treatment options and ultimately improve patient
management.
MATERIALS AND METHODS
Study design and patient characteristics
A total of 44 HCT recipients treated in the Bone Marrow Transplanta-
tion Unit of Vienna’s Medical University between 2007 and 2012
were enrolled in the study. In all, 22 patients suffered from aGVHD,
15 had clGVHD, and seven had csGVHD. Additional eight aGVHD
cases from an independent cohort from Hematology/Transplantation,
Hospital Saint Louis, Paris (collected in 2012), as well as ten cases of
non-HCT recipients with DHR collected between 2009 and 2012 in
the Dermatology Department of the University Hospital Zurich, were
included.
In all GVHD patients, the diagnosis of GVHD was based on the
National Institutes of Health (NIH) consensus criteria and confirmed
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by histopathology. At the time of biopsy, none of the aGVHD
patients were under corticosteroid treatment. Clinical aGVHD grad-
ing was based on modified Glucksberg criteria (Przepiorka et al.,
1995), and histopathological aGVHD grading was based on Lerner
criteria (Lerner et al., 1974). DHR patients clinically presented
generalized maculopapular exanthema (n¼ 7) or (sub)erythrodermia
(n¼ 3; for details, see Table 1). Patients with toxic epidermal
necrolysis or grade 4 cutaneous aGVHD were not included. For
cGVHD, the clinical and histological evaluations were performed
according to the NIH consensus criteria (Filipovich et al., 2005).
Corticosteroid responsiveness was defined as the reduction in GVHD
activity in one or more organs without progression in any organ or site
and the ability to taper corticosteroids. Patient characteristics of
GVHD and DHR patients are listed in Table 1. Psoriasis sections
for IH stainings were taken from routine biopsies for diagnostic
analysis.
The study was approved by the Ethics Committee of the Medical
University of Vienna (EK 607/07) and the Ethics Committee of the
University of Zurich (EK 647) and conducted according to the
Declaration of Helsinki principles. All study subjects gave written
informed consent and participated voluntarily.
Skin samples
6-mm skin punch biopsies were taken under local anesthesia.
One part was embedded in formalin and used for conventional
HE histopathological analysis, as well as for the elafin staining.
The residual tissue material was divided in half. One half was
used for TRIzol (Invitrogen Life Technologies, Vienna, Austria)
fixation (reverse transcriptase-PCR), and the other half was embedded
in optimal cutting temperature (OCT; TissueTek, Sakura Finetek
Europe B.V., Alphen aan der Rijn, Netherlands) compound (immu-
nohistology) and subsequently deep-frozen in liquid nitrogen. Tissue
specimens were stored at  20 1C (OCT) and  80 1C (TRIzol) until
further processing.
Evaluation of histopathological parameters and IH staining
for elafin
Details on the histopathological evaluation, as well as on the IH stain-
ing for elafin, can be found in Supplementary Material and Methods.
Quantification of epidermal elafin expression
To quantify epidermal elafin expression, slides were scanned using
the digital HistoFAXS imaging system (TissueGnostics GmbH). The
percentage of elafin-positive keratinocytes was measured using the
HistoQuest imaging analysis software (TissueGnostics GmbH). The
detection baseline was adapted to the isotype control, and all images
were acquired and analyzed using identical hardware and software
settings.
Immunofluorescence stainings
Frozen tissue was cut into 5-mm-thick sections and mounted on
capillary gap microscope slides (Dako, Glostrup, Denmark). Cryosec-
tions were air-dried for 20 minutes, fixed in ice-cold acetone (Sigma-
Aldrich, Vienna, Austria) for 10 minutes, and stored at  20 1C.
Triple immunofluorescence stainings on sections of GVHD patients
and healthy control (n¼ 7) were performed and evaluated as
previously described (Bru¨ggen et al., 2014). Negative controls were
obtained by substituting IgG for the primary antibody. Labeled cells
were expressed as the number of cells±SD per either millimeter
(mm) basement membrane (epidermis) or mm2 (dermis).
Real-time reverse transcriptase-PCR
After TRIzol lysis, the samples were thawed on ice and homogenized
with a FastPrep-24 homogenizer (MP Biomedicals; Solon, OH)
according to the manufacturer’s instructions. RNA concentration
was determined on a NanoDrop ND-100 spectrophotometer (Peqlab
Biotechnology; Erlangen, Germany). Reverse transcription, preampli-
fication, quantification, and data analysis were performed as pre-
viously described (Bru¨ggen et al., 2014). Details on the primers used
are listed in Supplementary Material and Methods.
Statistical analysis
All statistical analyses were performed using IBM SPSS Statistics 21 for
Windows (IBM, Armonk, NY). For all comparisons of means between
groups (elafin expression, epidermal thickness, infiltrate, PCR-data), a
Mann–Whitney test was used and a P-value ofo0.05 was considered
statistically significant. Spearman’s test was used to analyze
the correlation between clinical/histological grading and elafin
expression. Corticosteroid responsiveness and nonrelapse mortality
in elafin-high and elafin-low groups was evaluated with a X2
test. Log-rank test was used to compare the survival times.
Bonferroni correction for multiple comparisons was conducted and
a Bonferroni-adapted P-value of o0.01 was considered statistically
significant.
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